The Shionogi BACE1 aspartyl protease inhibitor, atabecestat (JNJ-54861911) is an oral, brain-penetrant compound that was advanced into the EARLY Ph. IIb/III clinical trial for treatment of preclinical Alzheimer’s disease (AD) patients. The starting point was identified from a phenotypic HTS, and was the first thiazine-based BACE1 disclosed [...]
< 1 minute read
Nov. 3, 2021
Atabecestat: The First Patented BACE1 Protease Inhibitor
atabecestat (JNJ-54861911)
first patented BACE1 protease inhib. of series Ph. II/III in Alzheimer’s, discontinued (tox.) from phenotypic screen and SBDD J. Med. Chem., Feb. 15, 2021 Shionogi Pharmaceutical, Osaka, JP
Loading...
